A compound sustained-released injection containing an angiogenesis inhibitor marimastat comprises sustained-released microspheres and a solvent. The sustained-released microspheres comprise a sustained-released adjuvant, an angiogenesis inhibitor selected from marimastat and fumagillin, and a cell toxicant selected from hydroxycamptothecin, mitozolomide, 4-carboxy temozolomide, docetaxel, oxaliplatin, sunplatinum, iphosphamide, lomustine, estramustine, fotemustine, semustine, etoposide, teniposide, vinblastine, anastrozole, fluorouracil and mitomycin c; and the solvent is a common solvent or a special solvent containing a suspending agent. The sustained-released adjuvant is selected from polifeprosan, poly(lactic acid), sebacic acid polymer such as poly(erucic acid dimmer-sebacic acid) and poly(fumaric acid-sebacic acid), EVAc, etc.; and the suspending agent has a viscosity of 100-3,000cp (20-30 DEG C) and is selected from sodium carboxymethyl cellulose, etc. The sustained-released microspheres can also be made into a sustained-released implant, which can enhance the curative effect of non-operative treatments such as chemotherapy and radiotherapy by intratumoral or peritumoral injection or placement.